ALSO NOTED: Shasun sets up NJ plant; Barrier gets a new CEO; Pharming gains grant; and much more...

> India's Shasun Chemicals has set up a processing unit for active pharmaceutical ingredients in New Jersey to supply U.S. customers. Report

> Chutes & Ladders: The chief operating officer of Barrier Therapeutics, Alfred Altomari, has been named CEO, succeeding Geert Cauwenbergh. Report

> Pharming has received a grant of €905,000 to research premature aging. Report

> German regulators have cleared Celgene's takeover of Pharmion. Release

> More than 100 allergic reactions, including one possible death, prompted Baxter International to recall its anti-clotting drug heparin. Report

> It's official: Merck's off-patent statin drug Mevacor can't go over-the-counter. Report

> The FDA has plans to review the controversial Enhance study. Report

> Is pharma addicted to producing blockbuster drugs? Report

And Finally… Opening up gorilla and chimpanzee reserves to tourists is raising fears that the animals will become infected by virulent human viruses. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.